Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C

Hepatology

Volumn 31, Issue 6, 2000, Pages 1338-1344

  Pol, Stanislas ^a   Nalpas, Bertrand ^a   Bourlière, Marc ^b   Couzigou, Patrice ^c   Tran, Albert ^d   Abergel, Armand ^e   Zarski, Jean Pierre ^f   Berthelot, Pierre ^a   Bréchot, Christian ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HÔpital Conception   (France)

^c Unit of Standard Care   (France)

^d De l'Archet   (France)

^e HÔTEL DIEU   (France)

^f Department of Pathology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; DEPRESSION; DRUG INDUCED DISEASE; DRUG MEGADOSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS HEPATITIS;

EID: 0034033749     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.8089     Document Type: Article

References (15)

1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, and the Hepatitis Interventional therapy group. Treatment of chronic hepatitis C with recombinant Interferon alpha. A multicenter randomized controlled trial. N Engl J Med 321:1989,1501-1506.
2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murrey L, Waggoner J, Goodman Z, et al. Recombinant Interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
3. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon in nonA-nonB hepatitis: a meta-analysis of randomised clinical trials. J Hepatol 1991;13:192-199.
4. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski J-P. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. HEPATOLOGY 1996;24:778-789.
5. Chemello L, Cavaletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995;23:8-12.
6. Lai M-Y, Kao J-H, Yang P-M, Wang J-T, Chen P-J, Chan K-W, Chu J-S, et al. Long-term efficacy of Ribavirin plus Interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312.
7. Reichard O, Norkrans G, Frydén A, Braconier J-H, Sonnerborg A, Weiland O, for the Swedish Study group. A randomized double-blind, placebo-controlled trial of Interferon-α2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-87.
8. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
9. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZH, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
10. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-1499.
11. Bellobuono A, Mondazzi L, Tempini S, Silini E, Vicari F, Ideo G. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepat 1997;4:185-191.
12. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalleto L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997;26:961-966.
13. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C, and a collaborative Study Group. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995;122:161-168.
14. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, et al. Factors predictive of response to Interferon-α therapy in hepatitis C virus infection. HEPATOLOGY 1994;19:1088-1094.
15. Thiers V, Jaffredo F, Tuveri R, Chodan N, Bréchot C. Development of a simple restriction fragment length polymorphism (RFLP) based assay for HCV genotyping and comparative analysis with genotyping and serotyping tests. J Virol Methods 1997;65:9-17.